Clinical Trial Update: Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant gemcitabine, epirubicin, and ABI-007 (GEA) in locally advanced or inflammatory breast cancer; study completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• gea (gemcitabine, epirubicin, ABI-007)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-11-30